Papadopoulos, Kyriakos P <br/><br/>
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  May 2014 
 - 2445-56 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-13-2403  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--pharmacology<br/>Drug Monitoring<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Quinoxalines--pharmacology<br/>Signal Transduction--drug effects<br/>Sulfonamides--pharmacology<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Outcome<br/>Young Adult